Full Press Release Details
Sciences, a Subsidiary of BioTime, Announces Release of GeneCards
Release Features showcasing of gene-relevant scientific conferences
ALAMEDA, Calif.--(BUSINESS WIRE)--December 6, 2013--LifeMap Sciences,
Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the
release of GeneCards , Version 3.11. The new
release is available at www.genecards.org. GeneCards
is a comprehensive online database that provides comprehensive
information on all human genes. It is accessed by professionals in many
institutions including academia, research hospitals, patent offices, and
leading biotech and pharma companies. LifeMap Sciences holds the
exclusive worldwide license to market GeneCards
from Yeda Research and Development Company Ltd., the commercial arm of
the Weizmann Institute of Science.
GeneCards 3.11 now showcases gene-related
scientific conferences, including links to ESCMID 2014 on Microbiology &
Infectious Diseases, AD/PD 2014 on Alzheimer's and Parkinson's disease
and ISPPD-9 on Pneumococci and Pneumococcal diseases.
Additional features of the new GeneCards release
More than 122,000 gene entries, including the world's largest arsenal
of ~77,000 non-protein-coding RNAs.
Revamped comprehensive version of the popular disease-gene list with
links to MalaCards (www.malacards.org), our Human
Enhanced information about genetic variations and disease mutations
Gene classifications from HGNC and IUPHAR
Information on protein-binding ligands from the International Union of
Basic and Clinical Pharmacology (IUPHAR)
Enhanced proteomics section with new tissue expression data from the
Improved presentation of expression in embryonic tissues from LifeMap
Discovery (discovery.lifemapsc.com) and new antibodies.
"It is a pleasure to see GeneCards making new progress in its mission to
cover all about human genes'. I am especially proud to see the new
information from the International Union of Basic and Clinical
Pharmacology, covering both gene-related binding molecules (ligands) and
protein classification. Along with our newly enhanced super-pathways and
novel proteome data, these items portray the inventiveness of our
academic team," said Professor Doron Lancet, Ph.D., The Ralph D. and
Lois R. Silver Professor of Human Genomics, at the Weizmann Institute of
"We continue focusing on making GeneCards
a go-to platform for the biomedical research community, and are looking
to expand our offerings of gene-related scientific conferences through
future collaborations," stated Yaron Guan-Golan, Chief Marketing Officer
of LifeMap Sciences.
About LifeMap Sciences, Inc.
LifeMap Sciences' (www.lifemapsc.com) core technology and
business is based on its Integrated Biomedical Knowledgebase and
discovery platform for biomedical research, which currently includes GeneCards :
the leading human gene database; LifeMap Discovery , the
database of embryonic development, stem cell research and regenerative
medicine; and MalaCards, the human disease database. LifeMap's
products are used in many institutions including academia, research
hospitals, patent offices, and leading biotechnology and pharmaceutical
companies. LifeMap is also engaged in therapeutics discovery, utilizing
LifeMap's proprietary platform to aid in the development of products for
the treatment of degenerative diseases, including utilizing BioTime's
proprietary, PureStem human progenitor cell lines. In addition
to its currently marketed products, LifeMap is pursuing several new
internet and informatics products with substantial rapid revenue growth
potential, leveraging its existing products and their large user base.
BioTime is a biotechnology company engaged in research and product
development in the field of regenerative medicine. Regenerative medicine
refers to therapies based on stem cell technology that are designed to
rebuild cell and tissue function lost due to degenerative disease or
injury. BioTime's focus is on pluripotent stem cell technology based on
human embryonic stem ("hES") cells and induced pluripotent stem ("iPS")
cells. hES and iPS cells provide a means of manufacturing every cell
type in the human body and therefore show considerable promise for the
development of a number of new therapeutic products. BioTime's
therapeutic and research products include a wide array of proprietary PureStem
progenitors, HyStem hydrogels, culture media,
and differentiation kits. BioTime is developing Renevia (a HyStem
product) as a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. In addition,
BioTime has developed Hextend , a
blood plasma volume expander for use in surgery, emergency trauma
treatment and other applications. Hextend is
manufactured and distributed in the U.S. by Hospira, Inc. and in South
Korea by CJ CheilJedang Corporation under exclusive licensing agreements.
BioTime is also developing stem cell and other products for research,
therapeutic, and diagnostic use through its subsidiaries:
OncoCyte Corporation is developing products and technologies to
diagnose and treat cancer.
ES Cell International Pte Ltd., a Singapore private limited company,
develops hES products for research use.
OrthoCyte Corporation is developing therapies to treat orthopedic
disorders, diseases and injuries.
ReCyte Therapeutics, Inc. is developing therapies to treat a variety
of blood and lymphatic vascular disorders, as well as products for
research using iPS and other cell reprogramming technology.
Cell Cure Neurosciences Ltd. is an Israel-based biotechnology company
focused on developing stem cell-based therapies for retinal and
neurological degenerative diseases. Its lead product is OpRegen
for the treatment of macular degeneration.
LifeMap Sciences, Inc. markets, sells and distributes GeneCards ,
the leading human gene database, as part of an integrated database
suite that also includes the LifeMap Discovery database of
embryonic development, stem cell research and regenerative medicine,
and MalaCards, the human disease database.
Asterias Biotherapeutics, Inc. is a newly formed subsidiary whose
first acquisition was the stem cell assets of Geron Corporation,
including patents and other intellectual property, biological